| Literature DB >> 35600971 |
Min Wang1, Peng Xu1, Bo Lei2,3,4,5.
Abstract
Developing bioactive biomaterials with highly controlled functions is crucial to enhancing their applications in regenerative medicine. Citrate-based polymers are the few bioactive polymer biomaterials used in biomedicine because of their facile synthesis, controllable structure, biocompatibility, biomimetic viscoelastic mechanical behavior, and functional groups available for modification. In recent years, various multifunctional designs and biomedical applications, including cardiovascular, orthopedic, muscle tissue, skin tissue, nerve and spinal cord, bioimaging, and drug or gene delivery based on citrate-based polymers, have been extensively studied, and many of them have good clinical application potential. In this review, we summarize recent progress in the multifunctional design and biomedical applications of citrate-based polymers. We also discuss the further development of multifunctional citrate-based polymers with tailored properties to meet the requirements of various biomedical applications.Entities:
Keywords: Bioactive materials; Bioactive polymers; Citrate-based biomaterials; Multifunctional modification; Tissue engineering
Year: 2022 PMID: 35600971 PMCID: PMC9096270 DOI: 10.1016/j.bioactmat.2022.04.027
Source DB: PubMed Journal: Bioact Mater ISSN: 2452-199X
Fig. 1Synthesis and properties of citrate prepolymer and citrate elastomers.
Fig. 2Development and biomedical applications of functional citrate-based biomaterials. PAA: poly (acrylic acid); PLCL: poly (l-lactic acid)-co-poly-(3-caprolactone); PLA: polylactide; PLLA: poly (l-lactic acid); PCL: polycaprolactone; F127: Pluronic; PEI: polyethyleneimine; EPL: ε-polylysine; PEG: polyethylene glycol.
Fig. 3Schematic diagram of further functionalized modified citrate-based polymers for vascular applications.
Functionalized citrate-based polymers for cardiovascular tissue engineering.
| Materials | Component | Properties | Tissue engineering | Ref. |
|---|---|---|---|---|
| POC-ePTFE | POC; ePTFE | Hydrophilicity; | Reduce platelets adhesion and macrophage infiltration; Inhibit thrombus; Promote endothelialization | 38,39 |
| Compliance | ||||
| Heparin-POC-ePTFE | POC; ePTFE; Heparin | Anti-thrombogenic; | Inhibit platelets adhesion and thrombus; Supported endothelial cells proliferation and specific phenotype expression | 40 |
| Anti-coagulant | ||||
| POCA- ePTFE | POC; ePTFE; Ascorbic acid | Intrinsic antioxidant | Reduce neointimal hyperplasia | 41 |
| POCR-ePTFE | POC; ePTFE; atRA | Antioxidant; Retinoid-like properties | Reduce macrophage and leukocyte infiltration; Inhibit the intimal formation; Hasten endothelialization | 42,43 |
| POC-PES | POC; PES | Enhanced hemocompatibility | Reduced fibrinogen adsorption and platelet adhesion | 44 |
| CUPE | POC; Polyurethane | Similar tensile strength, tunable burst pressure and suture retention | Inhibit platelets adhesion; Reduce inflammation; Anti-thrombosis | 45–47 |
| POMC | POC; Maleic acid | Controllable mechanical and degradation; Further Modification | Good cytocompatibility; | 48 |
| Reduce inflammation | ||||
| CUPOMC | POC; Maleic acid; Polyurethane | Increased tensile strength; | Support the cell adhesion and proliferation | 49 |
| Great processability | ||||
| POMaC | POC; Maleic anhydride | Increased elongation; Controlled physical structure and properties; Good biocompatibility | Minimally invasive delivery; Soft tissue engineering | 50–52 |
| AP | POMaC; Dopamine | Spatially varying adhesive properties | Biomaterial patches of supporting damaged tissue | 53 |
| PICO | POC; Itaconic acid | Tunable elasticity | Support cardiac tissue organization and viability | 54 |
| POC-PDDC | POC; PDDC | Biphasic tubular mimicked blood vessels; Shorten cells co-culture time | Small-diameter blood vessel scaffold | 55 |
| Porous POC- ECM proteins | POC; ECM proteins | Controlled pore size, porosity and shape | Support cell adhesion | 56 |
| POC-ECM | POC; ECM | Reduce platelet adhesion, Inhibit clotting | Improve thromboresistance and recellularization properties | 57 |
| PITCO | Dimethyl itaconate, Triethyl citrate; 1,8-octanediol | Fast crosslinking time; Semi-permeable; Appropriate elastic properties | Support the cells adhesion and proliferation | 59 |
| mPDDC | PDDC; glycidyl methacrylate | Customizable; Compressible, Self-expanding, Bioabsorbable, Antioxidant | Customize specific 3D-printed vascular scaffold | 60,62 |
| POCDA/PDDCDA | POC/PDDC; NO-donor | Controllable NO release; Compliance | Controlled cytostatic or cytotoxic effects; Inhibit neointimal hyperplasia | 63 |
| MA-POC/MA-PDDC | POC; PDDC; MA; Miscible NO-donor | Strong tensile strength; Radial compressive strength; Sustained release of NO | Local sustained release of NO in the vasculature | 64 |
| MTN | CUPE; GP1b; Anti-CD34 antibodies | Inhibit platelet aggregation; Reduce neointimal hyperplasia | Re-endothelialization | 66 |
| PPCN | Citric acid; PEG; PNIPAAm | Lower critical solution temperature; Intrinsic antioxidant properties | Sustained release of chemokine | 67 |
| PPC-ET/PEG | Citric acid; PEG; Ethyl thioglycolate | Injectable; Sustained release of citrate and growth factors | Reduce scar formation; | 68 |
| Increase new blood vessel formation |
POC: poly(octamethylene citrate); ePTFE: expanded polytetrafluoroethylene; atRA: all-trans retinoic acid; PES: polyethersulfone; GP1b: glycoprotein 1b; PDDC:poly(dodecamethylene citrate); ECM: extracellular matrix; PEG: polyethylene glycol; PNIPAAm: poly-N-isopropylacrylamide; NO-donor: N,N-Bis(2-hydroxyethyl)ethylenediamine . MA: 2-aminoethyl methacrylate; Miscible NO-donor: diazeniumdiolated N,N-diethyldiethylenetriamine.
Fig. 4Development and cardiovascular applications of functional POC-based biomaterials. (A) Synthesis schematic of the POC-Heparin ePTFE vascular graft; (B, C) SEM micrograph (B) and whole blood clot formation (C) of ePTFE, POC-coated ePTFE and POC-Heparin-coated ePTFE [40]; Copyright 2013, Elsevier. (D) Synthesis schematic of atRA-POC-ePTFE vascular graft; (E) The morphometric analysis for each graft and region, PA: proximal artery, PG: proximal graft, DG: distal graft, DA: distal artery, scale bar = 50 μm [43]; Copyright 2013, Elsevier. (F) Synthesis schematic of CUPE scaffold; (G) The morphology of CUPE scaffold and the state of fibroblast-seeded on CUPE scaffold; (H) Histology of in vivo response to each scaffold after 4-week [45]. Copyright 2008, Elsevier.
Fig. 5Schematic diagram of further functionalized modified citrate-based polymers for orthopedic applications.
Functionalized citrate-based polymers for bone tissue engineering.
| Materials | Component | Properties | Tissue engineering | Ref. |
|---|---|---|---|---|
| POC/PSC | POC; PSC | Improved mechanical performances | Good bioactivity; Stimulated bone regeneration | 82 |
| IBU-loaded SiO2/ | POC; Ibuprofen; Silica; | Highly interconnected porous network; Sustained IBU release; Antimicrobial property | Infectious bone defects repair | 83 |
| SPOC | POC; AS; GS | Controllable mechanical properties and degradation | Promote cell adhesion and proliferation; Increase ALP activity; mineralization | 84,85 |
| POC-POSS | POC; POSS | Highly tunable elastomeric behavior | Enhanced osteoblasts differentiation | 86 |
| GT/PCS/EPL | Gelatin; PCS; | Biomimetic elastomeric behavior; Controlled spinning diameter and degradation rate | Broad-spectrum antibacterial ability; Enhanced osteogenic bioactivity | 87 |
| PCS-SN | PCS; Silica | Uniformly distributed; Controlled elastomeric mechanical properties | Good histocompatibility; Promote osteoblasts adhesion and proliferation | 88 |
| PCS-BGN | PCS; BGN | Enhanced mechanical properties | Intrinsical biomineralization activity; Improved osteogenic differentiation | 89 |
| PEC-GS/BG | POC, BG | Improve angiogenesis and osteoblast differentiation | Enhance bone regeneration | 90 |
| PPM | PCS; PCL; miRNA complexes | Control miRNA loading and release | Enhance bone regeneration | 91 |
| POC-HA | POC; HA | Similar mechanical properties; Controlled degradation; Good biocompatibility | Good osteoblasts adhesion and proliferation; Osteogenic differentiation; mineralization | 92–96 |
| Porous POC-HA | POC; HA | Promotion of cell migration and tissue inward growth and diffusion | facilitate graft fixation and tissue integration | 97 |
| Porous POC-HA/PLL | POC; HA; poly(l-lactide) | Appropriate mechanical; Promote the infiltration and ingrowth of tissue | Promote graft fixation and anterior cruciate ligament reconstruction | 98 |
| POC-nHA | POC; smaller HA nanoparticles | Increased mechanical properties; Reduced degradation rate | Promote osteogenesis and craniofacial bone repair | 99 |
| POC-Click-HA | POC-Click; HA | Appropriate porosities; Controllable compressive strength | Promote osseointegration, periosteal remodeling and new bone formation | 101 |
| POC-M-click-HA | POC-Click; HA; MDEA | Rapidly degradable; Higher load and stiffness | Promote spinal fusion | 102 |
| CUPE-HA | CUPE; HA | Higher osteogenesis effect than POC-Click-HA | Calvarial defects repair | 103 |
| CBPBHA | CUPE; POC; HA | Higher compressive strength | Excellent osteoconductivity and osseointegration | 104 |
| CTBCs | POC; HA; Tannic acid; Silver nanoparticles | Improved compression strengths, degradation properties and antibacterial activity | Enhanced cell adhesion, proliferation and biomineralization; promote bone regeneration | 105 |
| iCMBA-HA | Citric acid; PEG; Dopamine; HA | Good injectability and adhesion; Suitable compressive strength and degradation rate | Increase bone mass and recover bone strength | 106 |
| CMWAs | Citric acid; PEG-PPG-PEG diol; Dopamine; Magnesium whitlockite | Excellent adhesion; Enhance the strength of bone-tendon bonding | Promote bone-tendon healing | 107 |
| PEGMC-HA | Citric acid; Maleic anhydride; PEG; HA | Controllable mechanical properties and viscoelastic; Injectable | promote ALP activity and calcium deposition of osteoblasts; osteonecrosis treatment | 108,109 |
| BPLP-PSer/HA | BPLP; Phosphoserine; HA | Promote osteogenic differentiation of MSCs | Promote bone regeneration | 110 |
| POC-HA/CS | POC; HA; Chitosan | Antibacterial activity | Antibacterial biodegradable bone screw | 113 |
| POC-ZnO | POC; Zinc oxide nanoparticles | Good antibacterial properties, Controllable release kinetics profile | Drug release and antiinfection-related tissue engineering | 114 |
| PCGL/GM | Citric acid; Glycerol; Gentamicin | Enhanced antibacterial efficacy | Antiinfection-related tissue engineering | 115 |
| PPCNG/BMP9-transduced cells | PPCN; Gelatin; MSCs/iCALs/iMAD | Thermoresponsive; Good angiogenic and osteogenic differentiation | Promote cranial defects repair | 116–118 |
| PPCNG-GO | PPCN; Gelatin; Graphene oxide | Thermoresponsive; Enhanced osteoinductive ability | Promote bone repair | 119 |
| PPCN–Sr/PPCN-phos/PPCN-cRGD | PPCN; Strontium/Phosphate/Arg-Gly-Asp peptide | Thermoresponsive; Induce osteoinductive and osteogenic differentiation | Bone regenerative engineering | 120 |
| POC-GP-Ca | POC; GP-Ca | Controlled mechanical properties and degradation | promoted osteogenic differentiation and bone regeneration | 121 |
POC: poly(octamethylene citrate); PSC: phytic acid-derived bioactive glass; AS: 3-aminopropyltriethoxysilane; GS: 3-(2,3-glycidoxy) propyltrimethoxysilane; POSS: polyhedral oligomeric silsesquioxanes; PCS: 3-aminopropyltriethoxysilane grafted POC; BGN: silica-based bioactive glasses nanoparticles; BG: bioactive glass; PCL: poly (ε-caprolactone); PPCN: thermoresponsive POC-based polymer comprised of citric acid, polyethylene glycol and poly-N-isopropylacrylamide; BMP9: bone morphogenetic protein-9; MSCs: mesenchymal stem cells; iCALs: murine-derived calvarial mesenchymal progenitor cells; iMAD: immortalized murine adipocyte; GP-Ca: calcium glycerophosphate; HA: hydroxyapatite; POC-Click: azide-alkyne modified POC polymer; MDEA: N-methyldiethanolamine; CUPE: POC-based polymer comprised of POC and polyurethane; PEG: polyethylene glycol; PEG-PPG-PEG diol: poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol); ALP: alkaline phosphatase; BPLP: amino acid-modified POC.
Fig. 6Development and orthopedic applications of silicon-doped POC-based biomaterials. (A) Synthesis schematic of CMSPC elastomers; (B) Mechanical properties of CMSPC hybrid elastomers; (C) Osteogenic differentiation of MC3T3-E1 cells after culture with CMSPC elastomers [85]; Copyright 2015, John Wiley and Sons. (D) Synthesis schematic of POC-POSS elastomers; (E) Calcium deposition mineralization on different elastomers with cells (left) and without cells (right) [86]; Copyright 2016, American Chemical Society. (F) Synthesis schematic of PCS-BGN elastomers; (G) Osteoblastic genes expressions of MC3T3-E1 after culture with PCS−BGN elastomers [89]; Copyright 2018, American Chemical Society. (H) Schematic diagram of PPM nanofibrous scaffold to recover bone tissue defect; (I) Micro-CT images of new bone formation in rat calvarial defect model; (J) Bone formation from the defect in 6 weeks [91]. Copyright 2019, John Wiley and Sons. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 7Development and orthopedic applications of POC-HA complexes. (A) PLLA and POC–HA screws; (B) Mineralization in SBF for POC–HA (65 wt% HA) at 3 days (left) and 15 days (right); (C) H&E stains of decalcified tissue (left) and femur bone (right) after 6 weeks of POC–HA implantation [92]; Copyright 2006, Elsevier. (D) Synthesis schematic of CTBCs; (E) Antibacterial ability of HA, THA, and AgTHA; (F) Histological staining at week 8 and 12 of the decalcified tissue sections containing the implanted materials [105]. Copyright 2020, John Wiley and Sons.
Fig. 8Schematic diagram of further functionalized modified citrate-based polymers for muscle and skin tissue applications.
Functionalized citrate-based polymers for muscle tissue engineering.
| Materials | Component | Properties | Tissue engineering | Ref. |
|---|---|---|---|---|
| POCfs | POC | High uniaxial elastic potential; MSCs loading and release | Promote muscle bundles formation and proteins expression; Bladder smooth muscle repair | 152 |
| POC/PLCL | POC; PLCL | Controllable mechanical property and degradation; | Promote myoblasts adhesion and proliferation; Myocardial tissue repair | 153 |
| PCEG | POC; Graphene; PEG | Controlled biodegradability; Enhanced elastomeric; Electrochemical conductivity | Promote myogenic differentiation and skeletal muscle regeneration | 154 |
| POCG-PEI600 | POC; PEG; PEI | Biodegradation and Biocompatibility | Enhance myotubes formation; Increase gene expression and protein level; | 155 |
| FPCP | POC; PEG; PEI; F127; PPy@PDA | Injectable; Adhesive; | Increase myogenic genes expression and MHC protein; Promote skeletal muscle regeneration | 156 |
POC: poly(octamethylene citrate); PLCL: poly (l-lactic acid)-co-poly-(3-caprolactone); MSCs: mesenchymal stem cells; VEGF: vascular endothelial growth factor; PEG: polyethylene glycol; PEI: polyethyleneimine; F127: Pluronic F-127; PPy@PDA: polypyrrole@polydopamine; MHC: myosin heavy chain.
Fig. 9Development and muscle and skin tissue applications of functional citrate-based biomaterials. (A) Synthesis schematic of conductive PCEG elastomers; (B) H&E staining of PCEG elastomers after implantation for 1 week and 4 weeks [154]; Copyright 2018, Elsevier. (C) Synthesis schematic of conductive PPCP nanofibrous matrix; (D) Photographs of S. aureus-infected wounds at 3, 7, 10, and 14 days; (E) Colonies derived from infected wound; (F) H&E stained images of wounds [175]. Copyright 2020, American Chemical Society.
Functionalized citrate-based polymers for skin tissue engineering.
| Materials | Component | Properties | Tissue engineering | Ref. |
|---|---|---|---|---|
| POC/PAA | POC; PAA | Mimicked dermis structure; Antibacterial activity; Enhance fibroblasts adhesion and proliferation | Bacterial infection wound healing | 173 |
| PCE/PCL | POC; EPL; PCL | Good tensile elastomeric; Hydrophilicity; Antibacterial ability; Promote collagen deposition and angiogenesis | Bacterial infection wound healing | 174 |
| PPCP | PCS; PLLA; Curcumin; Polydopamine | Antioxidant, Anti-inflammatory; Broad-spectrum antibacterial | Cutaneous tumor therapy and inflection-induced wound healing | 175 |
| POC-C/POC-T/POC-H/POC-M | POC; Quaternary ammonium; Phosphonium | Good antibacterial efficacy; appropriate mechanical properties | Antimicrobial wound dressings | 176 |
| CG-POCG | POC; PEG; chitosan; | Downregulate the pro-inflammatory cytokines; Upregulate angiogenic factors | Accelerate skin wound repair | 177 |
| FEA-PCEI | POC; PEG; PEI; Ibuprofen; F127; EPL; Sodium alginate | Injectable; Antibacterial; Increase anti-inflammatory M2 macrophage; Inhibiting inflammatory factors expression; | Accelerate wound healing and hair follicle neogenesis | 178 |
| FEPCGS | POC; PEG; Siloxane; F127; EPL | Injectable; antibacterial; anti-inflammatory; Promote fibroblasts proliferation and endothelial cells migration | MDRB-infected wound healing | 179 |
| iCMBA | Citric acid; PEG; Dopamin | High adhesion strength; Controllable mechanical properties and degradation properties | Hemostatic adhesive and wound closure | 180,181 |
| iCMBA-EPE/MgO | Citric acid; PEG-PPG-PEG diol; Magnesium oxide | High adhesive strength; Low swelling ratio; Good antibacterial and hemostatic ability | Promote wound closure and potential bone regeneration | 182 |
| AbAf iCs | iCMBA; 10-undecylenic acid | Strong wet tissue adhesion; Long-term antibacterial and antifungal abilities | Bacterial or fungal infections tissue engineering | 183 |
| POC/PLA | POC; PLA | Elastic; Hydrophilic; Sustained release aspirin | Wound dressing | 184 |
| H-HKUST-1 | PPCN; HKUST-1 NPs | Sustained release of copper ions; Antioxidant property; Promotion of collagen deposition and angiogenesis | Accelerate diabetic wound healing | 185 |
POC: poly(octamethylene citrate); PAA: poly (acrylic acid); PLA: polylactic acid; EPL: ε-polylysine; PCL: poly caprolactone; PCS: 3-aminopropyltriethoxysilane grafted POC; PLLA: poly (l-lactic acid); PEG: polyethylene glycol; PEI: polyethyleneimine; F127: Pluronic F-127; MDRB: multidrug resistant-bacteria; PEG-PPG-PEG diol: poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol); PPCN: thermoresponsive POC-based polymer comprised of citric acid, polyethylene glycol and poly-N-isopropylacrylamide; HKUST-1 NPs: copper metal-organic framework nanoparticles.
Fig. 10Schematic diagram of further functionalized modified citrate-based polymers for bioimaging applications.
Functionalized citrate-based polymers for bioimaging.
| Materials | Component | Properties | Tissue engineering | Ref. |
|---|---|---|---|---|
| BPLPs | POC; Amino acids | Tunable fluorescence emission; Photostability, Controlled degradation, Good processability; Biocompatibility | Fluorescent imaging probes | 218,219 |
| BPLP-Cys | POC; Cysteine | High fluorescence quantum yield | Bioimaging | 218 |
| BPLP- Ser | POC; Serine | Emission of 725 nm | Biodegradation quantum dots for bioimaging | 218 |
| PCGA | POC; PEG; Arginine | Water-soluble; Photoluminescence | Enhanced cell proliferation and Bioimaging | 222 |
| BPLP-Cys/ECM-Hep | POC; Cysteine; ECM; Heparin | Photoluminescence; Reduce platelet adhesion and intimal hyperplasia; Antioxidant activity | Vascular tissue engineering | 223,224 |
| DICT-NPs | Water-soluble/insoluble BPLP; MNPs | Dual-bioimaging of fluorescence and magnetic resonance; Tumor targeting selectivity | Diagnosis of cancer and other diseases | 225 |
| BPLP-PLLA | BPLP; | Intrinsic and stable fluorescence properties; Good processability | Tracking degradation | 226 |
| BPLP-PLLA-MTP | BPLP; | Tumor-targeted delivery of drugs | Tracking the delivery of drug and tumor therapy | 227 |
| BPLP-PLLA-PNBL-NPY | BPLP; | Uniform size; Good dispersion; photostability; Target breast tumors; Ultrasound imaging effect | Diagnosis of early breast cancer | 228 |
| BPLP-PLGA | BPLP; | Inherent photoluminescence properties; Controllable biodegradability; Good processability | Tracking degradation | 229 |
| UBPLP | POC; Cysteine; Urethane | Photoluminescent; Stable; Load and sustained release drug; elastic, Soft; Strong mechanical properties | Non-invasive real-time assays and drug delivery | 230 |
| BPLPAT | BPLP; Aniline tetramer | Intrinsic dual-mode imaging; Electrical conductivity; Excellent processability | Tissue engineering, bioimaging, drug delivery and cancer therapy | 231 |
| CHPO-ET/PEG | PHC; Cysteine/Serine; thiol acid; Multi-arm PEG | Injectability; Strong and tunable fluorescence properties; Sustained release of drugs | Fluorescence imaging | 232 |
| PSC-based | POC; AS; CSNW/SN/BGN | Controlled mechanical properties and Biodegradation; Tunable fluorescence emission; Photostability | Bioimaging and tissue regeneration | 233,235,87-89 |
| POCG-PEI | POC; PEG; PEI | Strong blue light emission; High photostability | Bioimaging | 234 |
| PCE | POC; EPL | High elongation and recovery rate; Antibacterial | Bioimaging | 237 |
POC: poly(octamethylene citrate); PEG: polyethylene glycol; MNPs: magnetic nanoparticles; PHC: poly(hexamethylene citrate); AS: 3-aminopropyltriethoxysilane; CSNW: ultralong copper sulfide nanowire; SN: Silica; BGN: silica-based bioactive glasses nanoparticles; EPL: ε-polylysine..
Fig. 11Schematic diagram of further functionalized modified citrate-based polymers for drug or gene delivery applications.
Functionalized citrate-based polymers for drug/gene delivery.
| Materials | Component | Properties | Tissue engineering | Ref. |
|---|---|---|---|---|
| Nanoporous POC | POC | Nanoporous; Low modulus; High elongation; Highly interconnected porous structure; sustained drug release | Drug delivery | 216 |
| CTNDDS | BPLP-PLLA; CAR T cells; DOX | Targeting ability to glioblastoma cells; pH-responsive drug sustained release | Tumor therapy and diagnosis | 242 |
| AP&SP-BWM-SPION/DOX | WBPLP-polyurethane; SPION; AP/SP, DOX | Reduce accumulation in the liver and kidney; Tumor targeted and magnetic resonance imaging | Tumor therapy and diagnosis | 243 |
| TFP-MNPs | WBPLP; PNIPAAm; Allylamine; MNP | Dual mode imaging; Magnetic targeted delivery; thermo-responsive sustained release of drugs | Tumor bioimaging and therapy | 244 |
| POC-based balloons | BPLP-PLGA or CUPE | Improve the delivery and retention of nanoparticles | Protein and drug delivery | 245 |
| BPLPL-based NPs | BPLP; PLLA; PLGA | Photoluminescence and tunable release kinetics | Fluorescent vascular drug delivery | 246 |
| PPEGMC | POC; Maleic acid PEG | Injectable; Controllable mechanical and degradation properties; Good compression recovery | Cell and drug delivery | 249 |
| NCH | PPEGMC; PEGDA; PC NPs | Excellent swelling and compressive strength; Good antibacterial ability; pH-responsive drug release | Skin cancer treatment and wound healing | 250 |
| Polyplex-containing POC | POC; PEI; pDNA | Higher loading and slower release pDNA | pDNA delivery and transfection | 251 |
| POCG-PEI | POC; PEG; PEI | Injectable; Water-soluble; Genes binding, delivery, protection and release | Gene delivery | 234 |
| PPFR | POC; PEG; PEI; RB; FA | Stable fluorescence properties; High siRNA transfection efficiency | Targeted label and gene therapy | 252 |
| FPRC | POC; PEG; PEI; RB; F127; CMC | Injectability; Self-healing ability; Stable red fluorescence emission; pH-responsive drug release | Tracking and melanoma therapy | 253 |
| PPM@ POCG-PEI/miRNA | PCS: PCL; POC; PEG; PEI; miRNA | Enhance elastomeric mechanical properties; Controlled miRNA loading and release | Promote bone regeneration | 91 |
| PCG-EPL | POC; PEG; EPL; miRNA | Effectively delivery miRNA33 agonist into adipocytes | Gene therapy of obesity | 254 |
POC: poly(octamethylene citrate); PEI: polyethyleneimine; PEG: polyethylene glycol; PEGDA: PEG-diacrylate; PC NPs: PLGA-carboxymethyl chitosan nanoparticles; RB: rhodamine B; FA: folic acid; F127: Pluronic F-127; CMC: carboxymethyl chitosan; PCS: 3-aminopropyltriethoxysilane grafted POC; PCL: poly caprolactone; EPL: ε-polylysine; CAR T cells: chimeric antigen receptor (CAR) T cells modified with targeted quadruple-mutant of interleukin-13; DOX: doxorubicin; SPION: super-paramagnetic iron oxide nanoparticle; AP: Y1R ligand; SP: antiphagocytosis; PNIPAAm: poly-N-isopropylacrylamide; MNP: iron oxide magnetic nanoparticles; PLLA: poly (l-lactic acid); PLGA: poly (lactic-co-glycolic acid).
The mechanical properties of citrate-based scaffolds.
| Elastomers | Young's modulus/MPa | Ultimate tensile strength/MPa | Ultimate elongation/% | Ref. |
|---|---|---|---|---|
| POC | 0.92–16.4 | ∼6.1 | ∼265 | 12 |
| CUPE | 2.53–29.82 | ∼41.07 | ∼222 | 45 |
| POMC | 0.07–1.3 | ∼0.37 | ∼322 | 48 |
| CUPOMC | 0.94–5.60 | ∼10.91 | ∼300 | 49 |
| POMaC | 0.04–1.52 | ∼0.99 | ∼441 | 50 |
| PICO | 0.04–1.48 | ∼0.30 | ∼40 | 54 |
| POC/PDDC | 1.1–1.3 | ∼2.20 | ∼310 | 55 |
| Porous POC | 0.0002–0.003 | / | ∼165 | 56 |
| PITCO | 0.01–0.05 | ∼0.03 | ∼115 | 59 |
| POCDA | ∼8.00 | ∼3.50 | ∼290 | 63 |
| PDDCDA | ∼2.8 | ∼2.70 | ∼195 | 63 |
| MA-POC | / | ∼10.60 | ∼30.9 | 64 |
| MA-PDDC | / | ∼6.50 | ∼50.2 | 64 |
| POCAS (PCS) | 5.0–22.1 | ∼14.7 | ∼134 | 84 |
| POCGS | 3.9–12.8 | ∼6.3 | ∼64 | 84 |
| CMSPC | 4.21–976.93 | ∼25.0 | ∼309 | 85 |
| POC-POSS | 2.54–66.21 | ∼5.98 | ∼336 | 86 |
| PCS-SN | 8.06–19.18 | ∼9.37 | ∼80 | 88 |
| PCS-BGN | 67.51–190.70 | ∼5.48 | ∼175 | 89 |
| PCS-CSNW | 27.40–70.83 | ∼10.74 | ∼146.03 | 235 |
| POC-Click | 10.00–280.00 | ∼42 | ∼350 | 100 |
| POCfs | ∼0.138 | / | ∼137 | 152 |
| POC-C/T/H | 0.30–1.06 | / | / | 176 |
| POC-M | ∼0.27 | / | / | 176 |
| iCMBA | 0.356–33.4 | ∼8.52 | ∼1582.5 | 180 |
| iCMBA-EPE/MgO | 1.98–8.70 | ∼4.40 | ∼244.8 | 182 |
| AbAf iCs | 0.19–51.56 | ∼3.31 | ∼415 | 183 |
| Nanoporous POC | ∼0.11 | / | ∼405 | 216 |
| BPLP-PLGA | 14.29–72.08 | ∼14.96 | ∼297.48 | 229 |
| CUBPLP | 13.29–18.87 | ∼49.41 | ∼334.87 | 230 |
| BPLPAT film | 6–40 | ∼7.00 | ∼80 | 231 |
| BPLPAT scaffold | 0.20–0.63 | 0.48 | / | 231 |
| PCE | 3.10–3.80 | ∼6.5 | ∼305 | 237 |
POC: poly(octamethylene citrate); CUPE: polyurethane-doped POC; POMC: maleic acid-crosslinked POC; CUPOMC: urethane-doped POMC; POMaC: maleic anhydride-crosslinked POC; PICO: itaconic acid-crosslinked POC; PDDC: poly(dodecamethylene citrate); POCDA: amine-containing POC; PDDCDA: amine-containing PDDC; MA-POC: methacrylated POC; MA-PDDC: methacrylated PDDC; POCAS (PCS): 3-aminopropyltriethoxysilane-modified POC; POCGS: 3-(2,3-glycidoxy) propyltrimethoxysilane-modified POC; CMSPC: HDI-crosslinked PCS; POC-POSS: POSS-doped POC; PCS-SN: silica nanoparticles-doped PCS; PCS-BGN: bioactive glass nanoparticles-doped PCS; PCS-CSNW: copper sulfide nanowire-doped PCS; POC-Click: azide-alkyne modified POC; POCfs: POC elastomeric thin film; iCMBA: dopamine cross-linked citrate; AbAf iCs: 10-undecylenic acid cross-linked iCMBA; POC-C/T/H: quaternary ammonium incorporated POC; POC-M: phosphonium incorporated POC; BPLP-PLGA: l-lactide and glycolide cross-linked BPLP; BPLPAT: aniline tetramer modified BPLPs; PCE: ε-polylysine modified POC.